Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 53 条
  • [1] Patients' decision-making process regarding participation in phase I oncology research
    Agrawal, Manish
    Grady, Christine
    Fairclough, Diane L.
    Meropol, Neal J.
    Maynard, Kim
    Emanuel, Ezekiel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4479 - 4484
  • [2] Cancer Trials Versus the Real World in the United States
    Al-Refaie, Waddah B.
    Vickers, Selwyn M.
    Zhong, Wei
    Parsons, Helen
    Rothenberger, David
    Habermann, Elizabeth B.
    [J]. ANNALS OF SURGERY, 2011, 254 (03) : 438 - 443
  • [3] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    Altman, DG
    Schulz, KF
    Moher, D
    Egger, M
    Davidoff, F
    Elbourne, D
    Gotzsche, PC
    Lang, T
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) : 663 - 694
  • [4] [Anonymous], 1978, The Belmont report: Ethical principles and guidelines for the protection of human subjects of research
  • [5] Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials
    Baquet, Claudia R.
    Ellison, Gary L.
    Mishra, Shiraz I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) : 3380 - 3386
  • [6] Treatment-subgroup interaction: An example from a published, phase II clinical trial
    Behrendt, Carolyn E.
    Gehan, Edmund A.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2009, 30 (03) : 279 - 281
  • [7] Factors and Outcomes of Decision Making for Cancer Clinical Trial Participation
    Biedrzycki, Barbara A.
    [J]. ONCOLOGY NURSING FORUM, 2011, 38 (05) : 542 - 552
  • [8] The Study of Accrual to Clinical Trials: Can we learn from studying who enters our studies?
    Brawley, OW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2039 - 2040
  • [9] Developing ethical strategies to assist oncologists in seeking informed consent to cancer clinical trials
    Brown, RF
    Butow, PN
    Butt, DG
    Moore, AR
    Tattersall, MHN
    [J]. SOCIAL SCIENCE & MEDICINE, 2004, 58 (02) : 379 - 390
  • [10] Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
    Bubley, GJ
    Carducci, M
    Dahut, W
    Dawson, N
    Daliani, D
    Eisenberger, M
    Figg, WD
    Freidlin, B
    Halabi, S
    Hudes, G
    Hussain, M
    Kaplan, R
    Myers, C
    Oh, W
    Petrylak, DP
    Reed, E
    Roth, B
    Sartor, O
    Scher, H
    Simons, J
    Sinibaldi, V
    Small, EJ
    Smith, MR
    Trump, DL
    Vollmer, R
    Wilding, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3461 - 3467